Specialty Equity Research and Professional Trading Service

Trades fully vetted with in-depth research based on a 3-pronged approach:
Fundamentals, Technicals and Options Activity

Welcome Jags!

Our mission is to deliver actionable, timely, fundamentally driven equity research to help you outperform the broader market. Our trading is based on a specific, tried-and-true approach that consistently delivers results. Read more about our methods.

You will receive top of the line research and market information, along with specific trade recommendations. Check out the subscription page for more details, and please read a welcome letter from Fahad Khalid, Chief Investment Officer.

Here’s to profitable trading!


For more research notes like these, sign-up for our free weekly newsletter, JaguarResearch.

September 11, 2018 | 11:32 AM by Jay Kunstman

Behind The Numbers – Limoneira (LMNR) Chilean Catalyst

Limoneira, an agribusiness and real estate development company, manages 11,430 acres of land centered on the production and marketing of citrus and specialty crops. The company is one of the…

Continue Reading »

September 7, 2018 | 1:50 PM by Fahad Khalid ★ Featured

Video: Presentation at MoneyShow San Francisco

Here is full presentation of JaguarAnalytics Chief Investment Officer, Fahad Khalid, at MoneyShow San Francisco on August 15, 2018

September 6, 2018 | 1:24 PM by Jay Kunstman

Catalyst Watch – Costa Hawkins

California Proposition 10, the Local Rent Control Initiative, is on the ballot in California as an initiated state statute on November 6th. Per Ballotpedia: What exactly is Costa Hawkins? It…

Continue Reading »

August 29, 2018 | 2:28 PM by Jay Kunstman

Behind The Numbers – Ooma (OOMA) Focusing on Strategic Initiatives

Ooma, through its communications solutions and connect services, has created a hybrid SaaS connectivity platform for residential and small business users in the United States and Canada. After the close…

Continue Reading »

August 8, 2018 | 2:30 PM by Jaguar

Deciphera Pharmaceuticals (DCPH) – Trio of Cancer Trials

Massachusetts-based Deciphera Pharmaceuticals (DCPH) is a clinical-stage biopharmaceutical company developing drugs to improve the lives of cancer patients. Its current pipeline is comprised of three drugs DCC-2618, DCC-3014 and Rebastinib….

Continue Reading »

Read more articles
Sign up for a four-week trial!

Password must meet the following requirements: